This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Placebo to match AZD9742; Drug: AZD9742

Study type: Interventional

Funder types: Industry

Identifiers

NCT01030224

D2690C00001

Details and patient eligibility

About

The main purpose of this study is to assess the safety, tolerability and PK of AZD9742 after single IV doses.

Enrollment: 48 patients

Sex: All

Ages: 23 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Provision of signed and dated, written informed consent prior to any study specific procedures.
• Clinically normal physical findings and laboratory values as judged by the investigator with normal ECG.
• Healthy male and female volunteers. Females must be of non childbearing potential.

Exclusion criteria

• Clinically significant illness or clinically relevant trauma, as judged by the investigator, within 4 weeks of the first administration of the Investigational Product
• History of any disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

48 participants in 2 patient groups, including a placebo group

AZD9742 IV Infusion

Experimental group

Description:

Active

Treatment:

Drug: AZD9742

Placebo to AZD9742 IV Infusion

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo to match AZD9742